<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chaudhuri S</submitter><funding>Wellcome Leap</funding><funding>Department for Science, Innovation and Technology</funding><funding>Royal Academy of Engineering</funding><funding>Wellcome Trust</funding><funding>Engineering and Physical Sciences Research Council</funding><pagination>7687-7697</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11480980</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>64(19)</volume><pubmed_abstract>Myotonic dystrophy type I (DM1) is the most common form of adult muscular dystrophy and is a severe condition with no treatment currently available. Recently, small-molecule ligands have been developed as targeted covalent inhibitors that have some selectivity for and covalently inhibit cyclin-dependent kinase 12 (CDK12). CDK12 is involved in the transcription of elongated RNA sections that results in the DM1 condition. The covalent bond is achieved after nucleophilic addition to a Michael acceptor warhead. Previous studies of the conformational preferences of thio-Michael additions have focused on characterizing the reaction profile based on the distance between the sulfur and β-carbon atoms. Rotamerism, however, has not been investigated extensively. Here, we use high-level quantum chemi</pubmed_abstract><journal>Journal of chemical information and modeling</journal><pubmed_title>Quantum Chemical Characterization of Rotamerism in Thio-Michael Additions for Targeted Covalent Inhibitors.</pubmed_title><pmcid>PMC11480980</pmcid><funding_grant_id>CiET2021_17</funding_grant_id><funding_grant_id>Q4Bio-2023-4424538316</funding_grant_id><funding_grant_id>EP/W028131/1</funding_grant_id><pubmed_authors>Hayes CJ</pubmed_authors><pubmed_authors>Chaudhuri S</pubmed_authors><pubmed_authors>Rogers DM</pubmed_authors><pubmed_authors>Hirst JD</pubmed_authors><pubmed_authors>Inzani K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Quantum Chemical Characterization of Rotamerism in Thio-Michael Additions for Targeted Covalent Inhibitors.</name><description>Myotonic dystrophy type I (DM1) is the most common form of adult muscular dystrophy and is a severe condition with no treatment currently available. Recently, small-molecule ligands have been developed as targeted covalent inhibitors that have some selectivity for and covalently inhibit cyclin-dependent kinase 12 (CDK12). CDK12 is involved in the transcription of elongated RNA sections that results in the DM1 condition. The covalent bond is achieved after nucleophilic addition to a Michael acceptor warhead. Previous studies of the conformational preferences of thio-Michael additions have focused on characterizing the reaction profile based on the distance between the sulfur and β-carbon atoms. Rotamerism, however, has not been investigated extensively. Here, we use high-level quantum chemi</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2025-04-04T07:40:45.766Z</modification><creation>2025-04-04T07:40:45.766Z</creation></dates><accession>S-EPMC11480980</accession><cross_references><pubmed>39265068</pubmed><doi>10.1021/acs.jcim.4c01379</doi></cross_references></HashMap>